Posted by Michael Wonder on 12 Jan 2017
NICE approves kidney cancer drug for NHS use
12 January 2017 - Patients with advanced kidney cancer will have routine NHS access to the drug everolimus following recommendations by NICE, rather than apply to the Cancer Drugs Fund.
NICE has approved everolimus (Afinitor, Novartis Pharmaceuticals) for routine use on the NHS as an option for patients with advanced renal cell carcinoma.
Everolimus is one of a series of drugs that has gone through a reappraisal process, where NICE is assessing the cost and clinical effectiveness of drugs currently in the old Cancer Drugs Fund.
